GlassScriptPhysician profile
John G Vanderwood
NPI 1205949013
$4,267.54
in general payments reported to CMS, 2019-2025
34 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $155 · 2021: $1,077 · 2022: $1,641 · 2023: $762 · 2024: $166 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,004.89 | 2021-2025 | Vraylar, Linzess, Qulipta |
| Novo Nordisk INC | $437.74 | 2020-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $407.63 | 2019-2023 | |
| Lilly USA, LLC | $352.92 | 2021-2023 | Taltz, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $204.55 | 2020-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Radius Health, INC. | $201.59 | 2021-2024 | Tymlos |
| Pfizer INC. | $169.87 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $163.77 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.07 | 2019-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $120.98 | 2021-2023 | |
| Exact Sciences Corporation | $118.92 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $114.45 | 2021-2022 | |
| Shire North American Group INC | $83.85 | 2019 | |
| Upsher-Smith Laboratories LLC | $72.21 | 2021 | |
| Merck Sharp & Dohme LLC | $70.79 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $57.17 | 2019-2020 | |
| Eisai INC. | $54.26 | 2021-2022 | |
| Corium, LLC | $48.75 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $48.48 | 2023 | Auvelity |
| Abbott Laboratories | $42.89 | 2021 | |
| Xeris Pharmaceuticals, INC. | $38.16 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $35.27 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $33.46 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.08 | 2020 | |
| Averitas Pharma INC. | $31.13 | 2023 | Qutenza |
| Idorsia Pharmaceuticals US INC | $28.74 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $24.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.80 | 2022 | |
| Lundbeck LLC | $21.64 | 2022 | |
| Chiesi USA, INC. | $19.28 | 2024 | Mycapssa |
| Phathom Pharmaceuticals, INC. | $18.03 | 2024 | Voquezna |
| Tris Pharma INC | $15.96 | 2023 | Dyanavel Xr |
| Amneal Pharmaceuticals LLC | $13.04 | 2022 | |
| Ibsa Pharma INC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vanderwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.